 Joshua Solomon
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 35 | 2023 | 464 | 9.770 |
Why?
| | Arthritis, Rheumatoid | 25 | 2023 | 989 | 5.360 |
Why?
| | Idiopathic Pulmonary Fibrosis | 12 | 2023 | 451 | 2.810 |
Why?
| | Connective Tissue Diseases | 9 | 2022 | 57 | 2.260 |
Why?
| | Immunoglobulin A | 2 | 2020 | 174 | 1.360 |
Why?
| | Myositis | 2 | 2023 | 41 | 1.280 |
Why?
| | Autoantibodies | 8 | 2023 | 1335 | 1.070 |
Why?
| | Tomography, X-Ray Computed | 6 | 2021 | 2436 | 0.930 |
Why?
| | Lung Diseases | 2 | 2021 | 718 | 0.820 |
Why?
| | Digestive System Surgical Procedures | 1 | 2022 | 91 | 0.790 |
Why?
| | Risk Adjustment | 1 | 2021 | 79 | 0.780 |
Why?
| | Rectal Neoplasms | 1 | 2022 | 121 | 0.770 |
Why?
| | Pyridones | 3 | 2023 | 119 | 0.760 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 209 | 0.730 |
Why?
| | Coronary Disease | 1 | 2021 | 356 | 0.670 |
Why?
| | Frailty | 1 | 2021 | 116 | 0.670 |
Why?
| | Scleroderma, Systemic | 3 | 2021 | 94 | 0.660 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2023 | 83 | 0.660 |
Why?
| | Lung | 12 | 2023 | 3664 | 0.600 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 304 | 0.580 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2016 | 25 | 0.580 |
Why?
| | Humans | 55 | 2024 | 118972 | 0.570 |
Why?
| | Vital Capacity | 7 | 2023 | 260 | 0.460 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.440 |
Why?
| | Emphysema | 1 | 2013 | 123 | 0.430 |
Why?
| | Prognosis | 6 | 2021 | 3443 | 0.430 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2011 | 25 | 0.390 |
Why?
| | Mortality | 3 | 2021 | 299 | 0.360 |
Why?
| | Smoking | 2 | 2017 | 1487 | 0.360 |
Why?
| | Aged | 18 | 2021 | 19657 | 0.360 |
Why?
| | Middle Aged | 21 | 2021 | 27617 | 0.340 |
Why?
| | Double-Blind Method | 3 | 2023 | 1687 | 0.330 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2017 | 58 | 0.320 |
Why?
| | Male | 27 | 2021 | 57801 | 0.320 |
Why?
| | Fibrosis | 2 | 2023 | 483 | 0.320 |
Why?
| | Disease Progression | 5 | 2023 | 2490 | 0.320 |
Why?
| | Kaplan-Meier Estimate | 5 | 2018 | 842 | 0.290 |
Why?
| | Female | 27 | 2021 | 61564 | 0.290 |
Why?
| | Lung Injury | 2 | 2024 | 210 | 0.280 |
Why?
| | Pulmonary Eosinophilia | 1 | 2006 | 25 | 0.280 |
Why?
| | Narcotics | 1 | 2006 | 50 | 0.270 |
Why?
| | Peptides, Cyclic | 3 | 2023 | 260 | 0.270 |
Why?
| | Risk Factors | 8 | 2023 | 9000 | 0.260 |
Why?
| | Radiation Injuries | 1 | 2006 | 131 | 0.260 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 681 | 0.250 |
Why?
| | Respiratory Function Tests | 6 | 2021 | 526 | 0.250 |
Why?
| | Environmental Pollutants | 1 | 2006 | 120 | 0.240 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 245 | 0.230 |
Why?
| | Survival Rate | 6 | 2019 | 1720 | 0.220 |
Why?
| | Immunomodulation | 1 | 2023 | 89 | 0.220 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 520 | 0.220 |
Why?
| | Treatment Outcome | 5 | 2023 | 9342 | 0.220 |
Why?
| | Rheumatologists | 1 | 2022 | 12 | 0.210 |
Why?
| | Pandemics | 4 | 2024 | 1355 | 0.210 |
Why?
| | Dyspnea | 1 | 2023 | 201 | 0.210 |
Why?
| | HIV Infections | 1 | 2016 | 2459 | 0.210 |
Why?
| | Therapeutic Irrigation | 1 | 2022 | 67 | 0.210 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1794 | 0.200 |
Why?
| | Mental Status and Dementia Tests | 1 | 2021 | 21 | 0.200 |
Why?
| | Patient Care | 1 | 2022 | 105 | 0.200 |
Why?
| | Life Expectancy | 1 | 2021 | 52 | 0.200 |
Why?
| | Rectum | 1 | 2022 | 157 | 0.190 |
Why?
| | Cause of Death | 3 | 2019 | 380 | 0.190 |
Why?
| | Serum Albumin | 1 | 2021 | 146 | 0.190 |
Why?
| | Mucin-5B | 2 | 2021 | 175 | 0.190 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 160 | 0.190 |
Why?
| | Attitude | 1 | 2022 | 231 | 0.190 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6561 | 0.180 |
Why?
| | Geriatric Assessment | 1 | 2021 | 185 | 0.180 |
Why?
| | Comorbidity | 2 | 2021 | 1527 | 0.180 |
Why?
| | Sarcoidosis | 2 | 2011 | 130 | 0.170 |
Why?
| | Hemoglobins | 1 | 2021 | 326 | 0.170 |
Why?
| | Pulmonary Fibrosis | 2 | 2012 | 303 | 0.170 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 30 | 0.170 |
Why?
| | Reproducibility of Results | 2 | 2023 | 2874 | 0.170 |
Why?
| | Acute Disease | 1 | 2021 | 940 | 0.160 |
Why?
| | United States | 11 | 2021 | 12555 | 0.160 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 254 | 0.160 |
Why?
| | Case-Control Studies | 5 | 2021 | 3171 | 0.160 |
Why?
| | Adult | 10 | 2023 | 31512 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1474 | 0.150 |
Why?
| | Extracellular Traps | 1 | 2017 | 40 | 0.150 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2017 | 41 | 0.150 |
Why?
| | Pneumocystis carinii | 1 | 2016 | 7 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2513 | 0.140 |
Why?
| | Critical Care | 1 | 2021 | 492 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1244 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 900 | 0.140 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 27 | 0.140 |
Why?
| | Rheumatoid Factor | 1 | 2017 | 156 | 0.140 |
Why?
| | Granuloma | 1 | 2016 | 87 | 0.140 |
Why?
| | Pedigree | 1 | 2017 | 485 | 0.140 |
Why?
| | Survival Analysis | 2 | 2017 | 1267 | 0.140 |
Why?
| | Thoracic Diseases | 1 | 2015 | 13 | 0.130 |
Why?
| | Sputum | 1 | 2017 | 290 | 0.130 |
Why?
| | Health Care Costs | 1 | 2018 | 394 | 0.130 |
Why?
| | Emergency Medical Services | 1 | 2021 | 589 | 0.120 |
Why?
| | Mortality, Premature | 1 | 2013 | 13 | 0.120 |
Why?
| | Bronchiolitis Obliterans | 1 | 2013 | 66 | 0.110 |
Why?
| | Mycophenolic Acid | 1 | 2013 | 79 | 0.110 |
Why?
| | Quality of Life | 1 | 2023 | 2366 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1125 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 294 | 0.110 |
Why?
| | Bronchial Diseases | 1 | 2012 | 34 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 355 | 0.100 |
Why?
| | Hospitalization | 1 | 2021 | 1785 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 827 | 0.100 |
Why?
| | Antigens, Human Platelet | 1 | 2011 | 8 | 0.100 |
Why?
| | Antibodies, Antinuclear | 1 | 2011 | 55 | 0.100 |
Why?
| | Lung Transplantation | 1 | 2013 | 263 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1384 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 290 | 0.090 |
Why?
| | Bleomycin | 1 | 2011 | 228 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.090 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 248 | 0.090 |
Why?
| | Biomarkers | 1 | 2019 | 3588 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 183 | 0.080 |
Why?
| | Incidence | 3 | 2021 | 2424 | 0.080 |
Why?
| | Retrospective Studies | 5 | 2023 | 12978 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2012 | 231 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1868 | 0.080 |
Why?
| | Prevalence | 3 | 2021 | 2326 | 0.070 |
Why?
| | Cohort Studies | 1 | 2015 | 5116 | 0.070 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1158 | 0.070 |
Why?
| | Young Adult | 5 | 2021 | 10793 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2006 | 322 | 0.060 |
Why?
| | Bronchi | 1 | 2024 | 242 | 0.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2023 | 89 | 0.050 |
Why?
| | Sex Factors | 3 | 2013 | 1781 | 0.050 |
Why?
| | Polymyositis | 1 | 2021 | 14 | 0.050 |
Why?
| | Dermatomyositis | 1 | 2021 | 22 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2006 | 545 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 58 | 0.050 |
Why?
| | Sex Distribution | 2 | 2012 | 351 | 0.050 |
Why?
| | Biopsy | 2 | 2014 | 1079 | 0.050 |
Why?
| | Canada | 1 | 2021 | 340 | 0.050 |
Why?
| | Methotrexate | 1 | 2021 | 227 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 37 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 1901 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 67 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 706 | 0.040 |
Why?
| | Forecasting | 1 | 2019 | 353 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4596 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 571 | 0.040 |
Why?
| | Hypersplenism | 1 | 2016 | 7 | 0.040 |
Why?
| | Global Health | 1 | 2019 | 310 | 0.040 |
Why?
| | Leukopenia | 1 | 2016 | 27 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 635 | 0.040 |
Why?
| | Adolescent | 3 | 2021 | 18480 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 996 | 0.030 |
Why?
| | Critical Illness | 1 | 2021 | 662 | 0.030 |
Why?
| | Arthritis | 1 | 2016 | 112 | 0.030 |
Why?
| | Alberta | 1 | 2013 | 12 | 0.030 |
Why?
| | Medicare | 1 | 2018 | 663 | 0.030 |
Why?
| | Age Factors | 2 | 2011 | 2995 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 861 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1882 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2674 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4552 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2012 | 117 | 0.030 |
Why?
| | Lung Compliance | 1 | 2011 | 49 | 0.030 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 69 | 0.030 |
Why?
| | Databases, Factual | 1 | 2016 | 1231 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 127 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 536 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2010 | 68 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 362 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 525 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2275 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 433 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 5690 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2011 | 613 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2011 | 462 | 0.020 |
Why?
| | Risk | 1 | 2011 | 853 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 983 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1636 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2011 | 671 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 6412 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4908 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 6471 | 0.010 |
Why?
| | Mice | 1 | 2011 | 15520 | 0.010 |
Why?
| | Animals | 1 | 2011 | 33381 | 0.010 |
Why?
|
|
Solomon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|